Move Beyond Proteomics Pumping Up Bruker Daltonics Revs, CEO Says
After slow revenue growth in Bruker BioSciences’ Daltonics division, the tide has turned and growth should continue at a healthy clip going forward, company CEO Frank Laukien told attendees at last week’s JPMorgan Healthcare Conference in San Francisco.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb or 360Dx Premium member?
Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.